ALKALI.NS
Alkali Metals Limited [ALKALI.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALKALI.NS Stock Summary
Top 10 Correlated ETFs
ALKALI.NS
Top 10 Correlated Stocks
ALKALI.NS
In the News
ALKALI.NS Financial details
Company Rating
Buy
Market Cap
1.16B
Income
15.51M
Revenue
853.37M
Book val./share
-
Cash/share
-
Dividend
2
Dividend %
1.45%
Employees
113
Optionable
No
Shortable
Yes
Earnings
23 May 2024
P/E
98.53
Forward P/E
-
PEG
-17.77
P/S
1.76
P/B
2.77
P/C
-
P/FCF
-
Quick Ratio
0.27
Current Ratio
1.1
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.52
EPS next Y
-
EPS next Q
-
EPS this Y
-16.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
11.49%
Revenue last 5Y
4.61%
Revenue Q/Q
45.75%
EPS Q/Q
285.85%
-
-
-
-
SMA20
8.49%
SMA50
-19.01%
SMA100
-2.54%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
6%
ROC
0.07%
Gross Margin
51%
Oper. Margin
6%
Profit Margin
2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
95.55-162.9
52W High
-32.1%
52W Low
+15.79%
RSI
47
Rel Volume
0.38
Avg Volume
28.24K
Volume
10.86K
Perf Week
-7.99%
Perf Month
-8.9%
Perf Quarter
-0.86%
Perf Half Y
-7.06%
-
-
-
-
Beta
0.595
-
-
Volatility
2.71%, 5.71%
Prev Close
-0.18%
Price
110
Change
-0.59%
ALKALI.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 69.15 | 68.91 | 54.38 | 88.2 | 86.65 | |
| Net income per share | 1.66 | 1.23 | -1.19 | 3.42 | 2.86 | |
| Operating cash flow per share | 6.78 | 9.27 | 1.29 | 10.99 | 10.99 | |
| Free cash flow per share | 3.92 | 5.53 | -2.24 | 8.14 | 7.9 | |
| Cash per share | 0.07 | 1.17 | 0.97 | 2.54 | 1.31 | |
| Book value per share | 51.1 | 49.38 | 48.48 | 51.15 | 51.92 | |
| Tangible book value per share | 50.91 | 49.26 | 48.42 | 51.15 | 51.92 | |
| Share holders equity per share | 51.1 | 49.38 | 48.48 | 51.15 | 51.92 | |
| Interest debt per share | 20.43 | 21.89 | 23.92 | 20.05 | 26.01 | |
| Market cap | 433.77M | 255.58M | 508.62M | 807.51M | 931.74M | |
| Enterprise value | 614.98M | 429.34M | 722.97M | 966.33M | 1.16B | |
| P/E ratio | 25.63 | 20.37 | -42.14 | 23.2 | 31.99 | |
| Price to sales ratio | 0.62 | 0.36 | 0.92 | 0.9 | 1.06 | |
| POCF ratio | 6.29 | 2.71 | 38.62 | 7.21 | 8.33 | |
| PFCF ratio | 10.86 | 4.54 | -22.32 | 9.74 | 11.58 | |
| P/B Ratio | 0.83 | 0.51 | 1.03 | 1.55 | 1.76 | |
| PTB ratio | 0.83 | 0.51 | 1.03 | 1.55 | 1.76 | |
| EV to sales | 0.87 | 0.61 | 1.31 | 1.08 | 1.31 | |
| Enterprise value over EBITDA | 7.97 | 6.06 | 11.74 | 8.35 | 10.71 | |
| EV to operating cash flow | 8.91 | 4.55 | 54.9 | 8.63 | 10.36 | |
| EV to free cash flow | 15.4 | 7.62 | -31.72 | 11.65 | 14.4 | |
| Earnings yield | 0.04 | 0.05 | -0.02 | 0.04 | 0.03 | |
| Free cash flow yield | 0.09 | 0.22 | -0.04 | 0.1 | 0.09 | |
| Debt to equity | 0.35 | 0.4 | 0.44 | 0.34 | 0.45 | |
| Debt to assets | 0.2 | 0.23 | 0.22 | 0.18 | 0.23 | |
| Net debt to EBITDA | 2.35 | 2.45 | 3.48 | 1.37 | 2.1 | |
| Current ratio | 1.07 | 1.12 | 1.19 | 1.23 | 1.14 | |
| Interest coverage | 1.57 | 1.4 | 1.11 | 2.98 | 2.02 | |
| Income quality | 4.08 | 7.08 | 3.61 | 2.16 | 2.9 | |
| Dividend Yield | 0.03 | 0.11 | 0 | 0.01 | 0.02 | |
| Payout ratio | 0.73 | 2.15 | 0 | 0.25 | 0.7 | |
| Sales general and administrative to revenue | 0 | 0 | 0.01 | 0 | 0.02 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to operating cash flow | -0.42 | -0.4 | -2.73 | -0.26 | -0.28 | |
| Capex to revenue | -0.04 | -0.05 | -0.06 | -0.03 | -0.04 | |
| Capex to depreciation | -0.85 | -1.1 | -1.07 | -0.75 | -0.73 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 43.71 | 37 | 35.96 | 62.72 | 57.8 | |
| ROIC | 0.05 | 0.05 | -0.21 | 0.07 | 0.05 | |
| Return on tangible assets | 0.02 | 0.01 | -0.01 | 0.04 | 0.03 | |
| Graham Net | -15.09 | -16.78 | -20.09 | -21.14 | -26.47 | |
| Working capital | 26.75M | 37.6M | 73M | 88.13M | 60.6M | |
| Tangible asset value | 518.39M | 501.55M | 493.05M | 510.54M | 526.33M | |
| Net current asset value | 170.39K | -23.82M | -27.04M | -6.7M | -44.35M | |
| Invested capital | 0.35 | 0.4 | 0.44 | 0.34 | 0.45 | |
| Average receivables | 175.19M | 133.83M | 136.35M | 153.67M | 138.32M | |
| Average payables | 153.54M | 135.61M | 151.44M | 196.66M | 193.38M | |
| Average inventory | 199.18M | 219.84M | 247.45M | 269.29M | 269.62M | |
| Days sales outstanding | 84.27 | 54.66 | 110.48 | 56.78 | 56.64 | |
| Days payables outstanding | 155.46 | 110.79 | 296.76 | 172.12 | 160.32 | |
| Days of inventory on hand | 220.76 | 211.36 | 437.31 | 218.72 | 245.22 | |
| Receivables turnover | 4.33 | 6.68 | 3.3 | 6.43 | 6.44 | |
| Payables turnover | 2.35 | 3.29 | 1.23 | 2.12 | 2.28 | |
| Inventory turnover | 1.65 | 1.73 | 0.83 | 1.67 | 1.49 | |
| ROE | 0.03 | 0.02 | -0.02 | 0.07 | 0.06 | |
| Capex per share | -2.86 | -3.73 | -3.53 | -2.85 | -3.09 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 18.62 | 26.42 | 16.75 | 16.54 | 24.11 | |
| Net income per share | 0.24 | 0.96 | 0.11 | 0.09 | 0.36 | |
| Operating cash flow per share | 2.12 | 2.16 | 2.22 | 2.25 | 2.3 | |
| Free cash flow per share | 2.12 | 2.16 | 2.22 | 2.25 | 2.3 | |
| Cash per share | 2.54 | 1.31 | 1.08 | 0.28 | 0 | |
| Book value per share | 51.2 | 51.92 | 51.92 | 49.87 | 0 | |
| Tangible book value per share | 0 | 51.92 | 0 | 49.87 | 0 | |
| Share holders equity per share | 51.2 | 51.92 | 51.92 | 49.87 | 0 | |
| Interest debt per share | 0.51 | 24.55 | 0.6 | 27.41 | 0.74 | |
| Market cap | 1.3B | 931.7M | 1.18B | 1.16B | 1.41B | |
| Enterprise value | 1.33B | 1.16B | 1.19B | 1.43B | 1.41B | |
| P/E ratio | 135.54 | 23.81 | 257.91 | 305.48 | 96.81 | |
| Price to sales ratio | 6.87 | 3.46 | 6.9 | 6.89 | 5.74 | |
| POCF ratio | 60.36 | 42.36 | 52.07 | 50.68 | 60.23 | |
| PFCF ratio | 60.36 | 42.36 | 52.07 | 50.68 | 60.23 | |
| P/B Ratio | 2.5 | 1.76 | 2.22 | 2.29 | 0 | |
| PTB ratio | 2.5 | 1.76 | 2.22 | 2.29 | 0 | |
| EV to sales | 7.01 | 4.31 | 6.96 | 8.51 | 5.74 | |
| Enterprise value over EBITDA | 68.41 | 32.02 | 66.97 | 74.23 | 49.04 | |
| EV to operating cash flow | 61.56 | 52.69 | 52.55 | 62.55 | 60.23 | |
| EV to free cash flow | 61.56 | 52.69 | 52.55 | 62.55 | 60.23 | |
| Earnings yield | 0 | 0.01 | 0 | 0 | 0 | |
| Free cash flow yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Debt to equity | 0 | 0.45 | 0 | 0.54 | 0 | |
| Debt to assets | 0 | 0.23 | 0 | 0.26 | 0 | |
| Net debt to EBITDA | 1.33 | 6.28 | 0.62 | 14.09 | 0 | |
| Current ratio | 0 | 1.14 | 0 | 1.1 | 0 | |
| Interest coverage | 1.67 | 1.87 | 1.06 | 1.14 | 2.26 | |
| Income quality | 8.98 | 2.25 | 19.81 | 24.11 | 6.43 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 16.49 | 33.5 | 11.44 | 10.23 | 0 | |
| ROIC | 0.01 | 0.02 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0 | 0 | 0 | |
| Graham Net | 2.54 | -26.47 | 1.08 | -26.98 | 0 | |
| Working capital | 25.86M | 60.6M | 10.98M | 43.36M | 0 | |
| Tangible asset value | 0 | 526.33M | 0 | 505.22M | 0 | |
| Net current asset value | 25.86M | -44.35M | 10.98M | -55.76M | 0 | |
| Invested capital | 0 | 0.45 | 0 | 0.54 | 0 | |
| Average receivables | 33.92M | 68.46M | 68.46M | 57.05M | 57.05M | |
| Average payables | 89.33M | 92.26M | 92.26M | 86.09M | 86.09M | |
| Average inventory | 148.52M | 141.12M | 141.12M | 161.54M | 161.54M | |
| Days sales outstanding | 0 | 45.81 | 0 | 60.98 | 0 | |
| Days payables outstanding | 0 | 127.61 | 0 | 238.69 | 0 | |
| Days of inventory on hand | 0 | 195.2 | 0 | 447.86 | 0 | |
| Receivables turnover | 0 | 1.96 | 0 | 1.48 | 0 | |
| Payables turnover | 0 | 0.71 | 0 | 0.38 | 0 | |
| Inventory turnover | 0 | 0.46 | 0 | 0.2 | 0 | |
| ROE | 0 | 0.02 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ALKALI.NS Frequently Asked Questions
What is Alkali Metals Limited stock symbol ?
Alkali Metals Limited is a IN stock and trading under the symbol ALKALI.NS
What is Alkali Metals Limited stock quote today ?
Alkali Metals Limited stock price is $110 today.
Is Alkali Metals Limited stock public?
Yes, Alkali Metals Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 28.24K
- Market Capitalization 1.16B
- Employee 113
- CEO Mr. Yerramilli Srirama R. Venkata Rao
- Headquarters Hyderabad,IN
- IPO Date 2008-11-06
-
Website
https://www.alkalimetals.com 
Alkali Metals Limited manufactures and sells chemical products in India and internationally. It offers API products; pyridine, acetylpyridine, alkyl borate, aminopyridine, bipyridine, bromopyridine, chloropyridine, cyanopyridine, cyclic, diethylamino pyridine, ethoxypyridine, fluoropyridine, hydroxypyridine, methoxypyridine, nitropyridine, picolylalcohol, pyridine n-oxide, pyrimidine, tetrazole, and triazole compounds; azaindole, potassium, sodium, and other metal derivatives; and boronic acids, fine chemicals, and DSSC and OLED materials. The company's products are used in various applications, such as pharma intermediates, anti retrovirals, flu vaccines, antibiotics, cardio/anti inflammation, agrochemicals, and automobiles. Alkali Metals Limited was incorporated in 1968 and is based in Hyderabad, India.
